immunoconjugates

(redirected from Immunoconjugate)
Also found in: Wikipedia.

immunoconjugates

monoclonal antibodies which are target-specific carriers for specific compounds such as plant or bacterial toxins, radionuclides, photoactive agents and chemotherapeutic drugs.
References in periodicals archive ?
Clinical evaluation of intraperitoneal Pseudomona s exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer.
Specific binding of this immunoconjugate to TF effectively inhibited tumor growth and caused regression of human melanoma in a mouse xenograft model (40).
SAR3419: an anti-CD19-Maytansinoid Immunoconjugate for the treatment of B-cell malignancies.
Antibody-targeted chemotherapy with CMC-544: a CD22targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies," Blood, vol.
This is a nicotine immunoconjugate IP18KLH that prevents the access of nicotine to the brain and has demonstrated to reduce the increase in dopamine output in the nucleus accumbens induced by nicotine as well as the reinstatement of nicotine-seeking behavior in rats.
The immunoconjugate contains an anti-EphA2 monoclonal antibody linked to the chemotherapy drug monomethyl auristatin phenylalanine (MMAF) through the non-cleavable linker maleimidocaproyl.
8) containing the HRP-labeled antibodies (concentration of immunoconjugate was 1 mg/mL) against the target analyte through the immunosorbent, allowing the immunoconjugate to form the sandwich complex of the unlabeled antibody, the analyte, and the labeled antibody on the immunosorbent, 7 minutes.
AC RN-321 is an anti-CD22/RNase immunoconjugate consisting of a B-cell specific monoclonal antibody chemically conjugated with ONCONASE.
1993) Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein.
Metastatic prostate cancer is diagnosed by radionuclide bone scans, computed tomographic (CT) scans, magnetic resonance imaging (MRI) scans, and most recently the ProstaScint[R] radionucleide scan which is an immunoconjugate containing a monoclonal antibody directed toward prostate-specific membrane antigen (PSMA) (Kahn et al.
What resulted is a drug/antibody immunoconjugate known as BR96-DOX.